| Sep 5 |
Biotech Stock Roundup: NVAX Vaccine Approval, ALNY, ATHA Stock Dive on Updates & More
|
| Sep 4 |
Dyne Therapeutics: Management Merry-Go-Round, Shaky Data Rock Wall Street
|
| Sep 4 |
Dyne Reports Mixed Data From DMD Study, Key Executives Step Down
|
| Sep 4 |
High-dose Spinraza meets study goal; Top Dyne executives exit
|
| Sep 3 |
Dyne stock tumbles 31% amid drug updates, management changes
|
| Sep 3 |
Dyne Called Its Sarepta-Rivaling Results 'Unprecedented,' But Its C-Suite Just Fled The Building
|
| Sep 3 |
Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy
|
| Sep 3 |
Boeing, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
|
| Sep 3 |
Dyne Therapeutics announces C-level executive changes
|
| Sep 3 |
Dyne Therapeutics Announces Key Leadership Appointments
|
